SEC
SNDX icon

Seven Eight Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Seven Eight Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,971
Closed -$1.56M – 935
2024
Q2 		$1.56M Buy
75,971
+66,332
+688% +$1.39M 0.16% 207
2024
Q1 		$229K Buy
+9,639
New +$215K 0.02% 563

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seven Eight Capital's SNDX Position: Q3 2024 in Review

Seven Eight Capital sold out of Syndax Pharmaceuticals (SNDX) in Q3 2024, closing a stake of 75,971 shares — an estimated $1.56M sold.

Seven Eight Capital first reported a position in SNDX in Q1 2024 and held it in 2 quarters. The position peaked at $1.56M in Q2 2024. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

  • Seven Eight Capital reported no remaining Syndax Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 75,971 Syndax Pharmaceuticals shares in Q3 2024, an estimated $1.56M.
  • Seven Eight Capital first reported a position in Syndax Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Seven Eight Capital's Syndax Pharmaceuticals position peaked at $1.56M in Q2 2024.
  • 210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.